Dianthus Therapeutics, Inc. (MGTA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1244223,
    "name": "Dianthus Therapeutics, Inc.",
    "stock_name": "Dianthus Therapeutics, Inc.",
    "full_name": "Dianthus Therapeutics, Inc.",
    "name_url": "stocks-analysis/dianthus-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "44.71",
    "chg": 2.43,
    "chgp": "5.75%",
    "dir": 1,
    "prev_price": "42.28",
    "mcapval": "1,023.59",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US2528281080",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.03 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dianthus-therapeutics-inc-1244223-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Dianthus Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dianthus-therapeutics-inc-technical-trend-changes-from-bullish-to-mildly-bullish-amid-stock-price-decline-3601318",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/DianthusTherape_technicaldot_3601318.png",
        "date": "2025-10-07 20:50:36",
        "description": "Dianthus Therapeutics, Inc. has recently adjusted its technical trends, reflecting mixed performance indicators. While some metrics show bullish signals, others indicate bearish trends. The company has outperformed the S&P 500 over the past year and year-to-date, showcasing its resilience in the competitive pharmaceuticals and biotechnology sector."
      },
      {
        "title": "Is Dianthus Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dianthus-therapeutics-inc-technically-bullish-or-bearish-3599302",
        "imagepath": "",
        "date": "2025-10-07 12:23:34",
        "description": "As of 3 October 2025, the technical trend for Dianthus Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance. However, the weekly RSI is bearish, and the weekly KST is bullish but the monthly KST is mildly bearish. Dow Theory shows a mildly bearish trend on the weekly timeframe, with no trend on the monthly. Bollinger Bands are mildly bullish on both weekly and monthly timeframes.\n\nIn terms of performance, the stock has returned 30.04% over the past month compared to the S&P 500's 4.15%, and a remarkable 2397.10% over the past three years against the S&P 500's 82.57%. Overall, the current stance is mildly bullish, driven primarily by the bullish daily moving averages and the weekly MACD...."
      },
      {
        "title": "Is Dianthus Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dianthus-therapeutics-inc-technically-bullish-or-bearish-3594032",
        "imagepath": "",
        "date": "2025-10-06 12:13:45",
        "description": "As of 3 October 2025, the technical trend for Dianthus Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the weekly RSI is bearish, suggesting some weakness. Bollinger Bands show a mildly bullish trend in both weekly and monthly time frames, and the KST is bullish weekly but mildly bearish monthly. The OBV is mildly bullish weekly, indicating some accumulation. \n\nIn terms of performance, the stock has returned 44.02% over the past month compared to the S&P 500's 4.15%, and it has a year-to-date return of 60.28% versus the S&P 500's 14.18%. Overall, the current technical stance is mildly bullish, with mixed signals across different indicators...."
      },
      {
        "title": "Is Dianthus Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dianthus-therapeutics-inc-technically-bullish-or-bearish-3592103",
        "imagepath": "",
        "date": "2025-10-05 11:58:58",
        "description": "As of 3 October 2025, the technical trend for Dianthus Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. However, the weekly RSI is bearish, suggesting potential weakness in the short term. The daily moving averages are bullish, supporting a positive outlook, while the KST shows a mixed signal with weekly bullishness and monthly mild bearishness. The Bollinger Bands are mildly bullish for both weekly and monthly periods, and the OBV is mildly bullish on a weekly basis. \n\nIn terms of performance, the stock has shown a strong 1-month return of 44.02% compared to the S&P 500's 4.15%, and a remarkable 3-year return of 2431.88% versus the S&P 500's 82.57%. Overall, the current stance is mildly bullish, with key indicators showing mixed signals but leaning towards positive momentum...."
      },
      {
        "title": "Dianthus Therapeutics Hits New 52-Week High of $40.16",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dianthus-therapeutics-hits-new-52-week-high-of-4016-3586073",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/DianthusTherape_priceRelatedfactors_3586073.png",
        "date": "2025-10-01 16:43:41",
        "description": "Dianthus Therapeutics, Inc. has achieved a new 52-week high of USD 40.16, significantly up from its low of USD 13.37, reflecting an impressive year-over-year performance. With a market cap of USD 1,024 million, the company faces challenges, including negative return on equity and no dividend yield, amid a competitive biotechnology landscape."
      },
      {
        "title": "Dianthus Therapeutics Hits Day High with 9.79% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dianthus-therapeutics-hits-day-high-with-979-surge-in-stock-price-3585921",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/DianthusTherape_priceRelatedfactors_3585921.png",
        "date": "2025-10-01 16:20:36",
        "description": "Dianthus Therapeutics, Inc. has seen a notable rise in stock performance, gaining 9.79% today and reaching an intraday high of USD 40.16. Over the past month, the stock has increased by 61.73%, despite facing challenges with negative results in recent quarters."
      },
      {
        "title": "Is Dianthus Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dianthus-therapeutics-inc-technically-bullish-or-bearish-3547707",
        "imagepath": "",
        "date": "2025-09-20 20:01:14",
        "description": "As of 5 September 2025, the technical trend for Dianthus Therapeutics, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, indicating positive momentum. Bollinger Bands are bullish on both weekly and monthly time frames, supporting the bullish stance. Daily moving averages also confirm a bullish trend. However, the KST shows a mildly bearish signal on the monthly, and the Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames.\n\nIn terms of performance, Dianthus has significantly outperformed the S&P 500 over the past month with a return of 85.45% compared to 2.33%. Year-to-date, the stock has returned 78.30% versus the S&P 500's 12.22%. Overall, the current technical stance is bullish with strong momentum indicators driving this outlook...."
      },
      {
        "title": "Is Dianthus Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dianthus-therapeutics-inc-overvalued-or-undervalued-3543999",
        "imagepath": "",
        "date": "2025-09-20 18:34:46",
        "description": "As of 21 March 2024, the valuation grade for Dianthus Therapeutics, Inc. has moved from does not qualify to risky, indicating increased concern regarding its financial health. The company appears to be overvalued given its negative earnings and high valuation ratios, including a Price to Book Value of 1.84, an EV to Sales ratio of 52.61, and a ROE of -30.65%. \n\nIn comparison to its peers, Dianthus has a significantly lower EV to EBITDA ratio of -2.94 compared to Syndax Pharmaceuticals, Inc. at -3.8242 and Rayzebio, Inc. at -46.3970, highlighting its relative weakness. Additionally, while the stock has shown strong short-term performance with a 1-month return of 85.45% compared to the S&P 500's 2.33%, its long-term performance remains concerning, with a 5-year return of -68.53% against the S&P 500's 96.61%. This suggests that despite recent gains, the overall valuation remains precarious...."
      },
      {
        "title": "Dianthus Therapeutics Hits New 52-Week High of $39.87",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dianthus-therapeutics-hits-new-52-week-high-of-3987-3537151",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/DianthusTherape_priceRelatedfactors_3537151.png",
        "date": "2025-09-19 13:12:41",
        "description": "Dianthus Therapeutics, Inc. has achieved a new 52-week high of USD 39.87, reflecting an 81.09% increase over the past year. With a market capitalization of USD 1,024 million, the company has shown resilience despite losses, and its stock has significantly outperformed the S&P 500 during the same period."
      }
    ],
    "total": 15,
    "sid": "1244223",
    "stock_news_url": "https://www.marketsmojo.com/news/dianthus-therapeutics-inc-1244223"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Dianthus Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Performance Indicators

2025-10-07 20:50:36

Dianthus Therapeutics, Inc. has recently adjusted its technical trends, reflecting mixed performance indicators. While some metrics show bullish signals, others indicate bearish trends. The company has outperformed the S&P 500 over the past year and year-to-date, showcasing its resilience in the competitive pharmaceuticals and biotechnology sector.

Is Dianthus Therapeutics, Inc. technically bullish or bearish?

2025-10-07 12:23:34

As of 3 October 2025, the technical trend for Dianthus Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance. However, the weekly RSI is bearish, and the weekly KST is bullish but the monthly KST is mildly bearish. Dow Theory shows a mildly bearish trend on the weekly timeframe, with no trend on the monthly. Bollinger Bands are mildly bullish on both weekly and monthly timeframes. In terms of performance, the stock has returned 30.04% over the past month compared to the S&P 500's 4.15%, and a remarkable 2397.10% over the past three years against the S&P 500's 82.57%. Overall, the current stance is mildly bullish, driven primarily by the bullish daily moving averages and the weekly MACD....

Is Dianthus Therapeutics, Inc. technically bullish or bearish?

2025-10-06 12:13:45

As of 3 October 2025, the technical trend for Dianthus Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the weekly RSI is bearish, suggesting some weakness. Bollinger Bands show a mildly bullish trend in both weekly and monthly time frames, and the KST is bullish weekly but mildly bearish monthly. The OBV is mildly bullish weekly, indicating some accumulation. In terms of performance, the stock has returned 44.02% over the past month compared to the S&P 500's 4.15%, and it has a year-to-date return of 60.28% versus the S&P 500's 14.18%. Overall, the current technical stance is mildly bullish, with mixed signals across different indicators....

Is Dianthus Therapeutics, Inc. technically bullish or bearish?

2025-10-05 11:58:58

As of 3 October 2025, the technical trend for Dianthus Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. However, the weekly RSI is bearish, suggesting potential weakness in the short term. The daily moving averages are bullish, supporting a positive outlook, while the KST shows a mixed signal with weekly bullishness and monthly mild bearishness. The Bollinger Bands are mildly bullish for both weekly and monthly periods, and the OBV is mildly bullish on a weekly basis. In terms of performance, the stock has shown a strong 1-month return of 44.02% compared to the S&P 500's 4.15%, and a remarkable 3-year return of 2431.88% versus the S&P 500's 82.57%. Overall, the current stance is mildly bullish, with key indicators showing mixed signals but leaning towards positive momentum....

Dianthus Therapeutics Hits New 52-Week High of $40.16

2025-10-01 16:43:41

Dianthus Therapeutics, Inc. has achieved a new 52-week high of USD 40.16, significantly up from its low of USD 13.37, reflecting an impressive year-over-year performance. With a market cap of USD 1,024 million, the company faces challenges, including negative return on equity and no dividend yield, amid a competitive biotechnology landscape.

Dianthus Therapeutics Hits Day High with 9.79% Surge in Stock Price

2025-10-01 16:20:36

Dianthus Therapeutics, Inc. has seen a notable rise in stock performance, gaining 9.79% today and reaching an intraday high of USD 40.16. Over the past month, the stock has increased by 61.73%, despite facing challenges with negative results in recent quarters.

Is Dianthus Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:01:14

As of 5 September 2025, the technical trend for Dianthus Therapeutics, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, indicating positive momentum. Bollinger Bands are bullish on both weekly and monthly time frames, supporting the bullish stance. Daily moving averages also confirm a bullish trend. However, the KST shows a mildly bearish signal on the monthly, and the Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. In terms of performance, Dianthus has significantly outperformed the S&P 500 over the past month with a return of 85.45% compared to 2.33%. Year-to-date, the stock has returned 78.30% versus the S&P 500's 12.22%. Overall, the current technical stance is bullish with strong momentum indicators driving this outlook....

Is Dianthus Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:34:46

As of 21 March 2024, the valuation grade for Dianthus Therapeutics, Inc. has moved from does not qualify to risky, indicating increased concern regarding its financial health. The company appears to be overvalued given its negative earnings and high valuation ratios, including a Price to Book Value of 1.84, an EV to Sales ratio of 52.61, and a ROE of -30.65%. In comparison to its peers, Dianthus has a significantly lower EV to EBITDA ratio of -2.94 compared to Syndax Pharmaceuticals, Inc. at -3.8242 and Rayzebio, Inc. at -46.3970, highlighting its relative weakness. Additionally, while the stock has shown strong short-term performance with a 1-month return of 85.45% compared to the S&P 500's 2.33%, its long-term performance remains concerning, with a 5-year return of -68.53% against the S&P 500's 96.61%. This suggests that despite recent gains, the overall valuation remains precarious....

Dianthus Therapeutics Hits New 52-Week High of $39.87

2025-09-19 13:12:41

Dianthus Therapeutics, Inc. has achieved a new 52-week high of USD 39.87, reflecting an 81.09% increase over the past year. With a market capitalization of USD 1,024 million, the company has shown resilience despite losses, and its stock has significantly outperformed the S&P 500 during the same period.

View All News